Innocan Pharma宣布了向哥廷根小型猪施用LPT-CBD的良好结果，提供了一个良好的转化模型，并提供了公司更新-动脉网

Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs, providing a good translational model and Provides Corporate Update

CISION 等信源发布 2025-07-04 04:04



可切换为仅中文







HERZLIYA,

赫兹利亚，

Israel

以色列

and

和

CALGARY, AB

卡加立，阿尔伯塔省

，

July 3, 2025

2025年7月3日

/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB:

/PRNewswire/ -- Innocan制药公司（CSE: INNO）（FSE: IP4）（OTCQB:

INNPF

内部合作伙伴框架平台

) ('Innocan' or the 'Company'), a pioneer in the pharmaceutical and biotechnology industries, announces the acceptance for publication of a research article entitled

）（“Innocan”或“公司”），制药和生物技术行业的先驱，宣布接受一篇题为

'Liposomal-Cannabidiol Injection: Preliminary Insights into Pharmacokinetics and Safety Characteristics in Göttingen Minipigs and Rabbits'

脂质体大麻二酚注射液：哥廷根小型猪和兔体内药代动力学及安全性特征的初步见解

in the esteemed journal

在权威期刊上发表

Precision Nanomedicine

精准纳米医学

。

The study demonstrates promising results of prolonged release and a favorable safety profile of CBD following a single subcutaneous administration of LPT-CBD in minipigs.

该研究显示，在迷你猪中单次皮下注射LPT-CBD后，CBD的缓释效果和安全性表现良好。

Corporate Updates

公司更新

Resignation of Director and Executive Chairman

董事和执行主席辞职

Ron Mayron

朗·梅隆

has resigned as Executive Chairman and a Director of the Company effective

已辞去公司执行董事长及董事职务，自即日起生效

July 1, 2025

2025年7月1日

. Mr. Mayron will remain with the Company for three additional months as a Special Consultant for the Company. In his place, Iris Bincovich, a current Director of the Company, will be temporarily holding the position of Chair of the Company.

梅伦先生将继续以公司特别顾问的身份留任三个月。接替他的是公司现任董事艾丽丝·宾科维奇，她将暂时担任公司主席一职。

Iris Bincovich, Chief Executive Officer and Chair of the Company stated 'we are grateful to Ron, one of the Company's founders, for his meaningful contributions over the past several years. His dedication and leadership have been greatly appreciated. We wish Ron the best of luck in his future endeavors.'.

Iris Bincovich，公司首席执行官兼主席表示：“我们非常感谢公司的创始人之一Ron在过去几年中作出的有意义的贡献。他的奉献精神和领导才能备受赞赏。我们祝愿Ron在未来的发展中一切顺利。”

Grants of RSU's and Stock Options

授予限制性股票单位和股票期权

在

July 2, 2025

2025年7月2日

, the Company granted an aggregate of 23,050,000 Restricted Share Units ('RSUs') to certain directors, officers, employees and consultants of the Company, payable in common shares of the Company upon satisfaction of various milestone-based vesting conditions. On

公司向某些董事、高级职员、员工和顾问授予了总计23,050,000份受限股份单位（“RSUs”），在满足各种基于里程碑的归属条件后，可支付为公司的普通股。

July 2, 2025

2025年7月2日

, the Company also granted an aggregate of 1,950,000 stock options of the Company (the 'Options') at an exercise price of

，公司还授予了总计1,950,000份公司股票期权（“期权”），行权价格为

$0.225

0.225美元

with a five-year expiry date to various employees of the Company. The RSUs and the Options were granted under the Company's stock option plan as most recently amended on

有效期为五年，授予公司的不同员工。RSUs和期权是根据公司最近修订的股票期权计划授予的，

June 26, 2025

2025年6月26日

. All RSU's, Options and underlying common shares are subject to a hold period of four months and one day pursuant to the policies of the Canadian Securities Exchange.

所有RSU、期权及相关的普通股均需遵守加拿大证券交易所规定的四个月零一天的持有期。

About Innocan

关于Innocan

Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle.

Under this segment, Innocan focuses on advanced, targeted online sales, through its BI Sky Global Ltd. subsidiary. .

在此部分下，Innocan 通过其子公司 BI Sky Global Ltd. 专注于先进、有针对性的在线销售。

www.innocanpharma.com

For further information, please contact:

如需更多信息，请联系：

For Innocan Pharma Corporation:

对于Innocan制药公司：

Iris Bincovich, CEO

艾丽丝·宾科维奇，首席执行官

+1 5162104025

+972-54-3012842

+442037699377

info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大证券交易所及其监管服务提供商均未审查或对本公告的充分性或准确性承担责任。

Caution regarding forward-looking information

关于前瞻性信息的注意事项

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws.

本新闻稿中包含的某些信息，包括但不限于有关研发、合作、向美国食品药品监督管理局（FDA）及其他监管机构提交潜在申请、未来可能达成的监管里程碑、治疗某些疾病及其他由研究活动和/或公司产品带来的潜在治疗效果、所需的监管批准及市场进入时间等信息，均属于适用证券法意义上的前瞻性信息。

By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements..

鉴于其性质，前瞻性信息受众多风险和不确定性的影响，其中一些超出Innocan的控制范围。本新闻稿中包含的前瞻性信息基于Innocan提出的某些关键预期和假设，包括对产品预期效益、满足不同司法管辖区监管要求以及顺利完成必要生产和分销安排的预期和假设。

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors.

前瞻性信息受各种风险和不确定性的影响，可能导致实际结果和经验与此新闻稿中表达的预期结果或期望存在重大差异。主要风险和不确定性包括但不限于：全球和当地（国家）总体经济、市场和商业状况；政府和监管要求以及政府当局的行动；与供应商、制造商、客户、业务合作伙伴和竞争对手的关系。

There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements.

产品分销的性质本身也存在一些风险，包括进出口事务、未能获得任何所需的监管和其他批准（或未能及时获得），以及各市场中产品投入和成品的可用性。进入市场的预期时间表可能因多种原因而发生变化，包括无法确保必要的监管要求，或需要额外时间来完成和/或满足制造和分销安排。

As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at .

由于上述原因，读者不应过分依赖本新闻稿中关于产品分销发布时间的前瞻性信息。影响Innocan的其他风险的全面讨论也可以在Innocan的公开报告和文件中找到，这些报告和文件可以在Innocan的资料页面查看。

www.sedar.com

。

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law..

读者应注意，不应过分依赖前瞻性信息，因为实际结果可能与前瞻性信息有重大差异。Innocan 不会因任何新信息、未来事件或其他原因而更新、更正或修改任何前瞻性信息，除非适用法律要求。

Logo -

标志 -

https://mma.prnewswire.com/media/2570689/5400283/Innocan_Pharma_Logo.jpg

SOURCE Innocan Pharma Corporation

来源：Innocan制药公司

WANT YOUR COMPANY'S NEWS

希望贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+